Reveiwing, one can note that we have our first two-time entry......
03/25/99 VRTX, 3-D structure of ribavirin bound to IMPDH
03/10/99 MLNM, clones mahogany, obesity target or lab curiosity?
03/09/99 VRTX, initiates phase I trial with p38 MAP kinase inhibitor
03/08/99 CNTO, sales force leverage, LMW heparin with PNU
03/04/99 AGPH, describes crystal structure for VEGFR2 kinase
03/02/99 INCY, using new chemistry from Amersham Pharmacia, flying
03/01/99 GLIA, finishes single-dose portion of phase I, GT-2331
03/01/99 GILD, NXTR merger
02/26/99 MEDI/Ixsys, MAb alliance, including anti-alpha-v beta-3
02/25/99 ONXX, Bayer select lead compound, ras pathway inhibitor |
